GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:019873821 | Liver | HCC | cell-cell signaling by wnt | 247/7958 | 446/18723 | 2.11e-08 | 4.96e-07 | 247 |
GO:004873222 | Liver | HCC | gland development | 242/7958 | 436/18723 | 2.26e-08 | 5.28e-07 | 242 |
GO:001605521 | Liver | HCC | Wnt signaling pathway | 245/7958 | 444/18723 | 3.68e-08 | 8.09e-07 | 245 |
GO:003011121 | Liver | HCC | regulation of Wnt signaling pathway | 180/7958 | 328/18723 | 3.62e-06 | 4.72e-05 | 180 |
GO:003017721 | Liver | HCC | positive regulation of Wnt signaling pathway | 81/7958 | 140/18723 | 1.73e-04 | 1.36e-03 | 81 |
GO:006056011 | Liver | HCC | developmental growth involved in morphogenesis | 124/7958 | 234/18723 | 7.37e-04 | 4.47e-03 | 124 |
GO:00016553 | Liver | HCC | urogenital system development | 170/7958 | 338/18723 | 2.15e-03 | 1.08e-02 | 170 |
GO:00018222 | Liver | HCC | kidney development | 148/7958 | 293/18723 | 3.25e-03 | 1.49e-02 | 148 |
GO:00720012 | Liver | HCC | renal system development | 152/7958 | 302/18723 | 3.45e-03 | 1.56e-02 | 152 |
GO:006145811 | Liver | HCC | reproductive system development | 205/7958 | 427/18723 | 1.16e-02 | 4.27e-02 | 205 |
GO:0016055110 | Thyroid | PTC | Wnt signaling pathway | 217/5968 | 444/18723 | 3.71e-14 | 2.30e-12 | 217 |
GO:0198738110 | Thyroid | PTC | cell-cell signaling by wnt | 217/5968 | 446/18723 | 6.68e-14 | 3.73e-12 | 217 |
GO:0030111110 | Thyroid | PTC | regulation of Wnt signaling pathway | 163/5968 | 328/18723 | 1.05e-11 | 4.29e-10 | 163 |
GO:0048732113 | Thyroid | PTC | gland development | 193/5968 | 436/18723 | 2.88e-08 | 6.42e-07 | 193 |
GO:000182215 | Thyroid | PTC | kidney development | 133/5968 | 293/18723 | 7.57e-07 | 1.18e-05 | 133 |
GO:003017719 | Thyroid | PTC | positive regulation of Wnt signaling pathway | 72/5968 | 140/18723 | 1.16e-06 | 1.69e-05 | 72 |
GO:000165517 | Thyroid | PTC | urogenital system development | 149/5968 | 338/18723 | 1.41e-06 | 2.01e-05 | 149 |
GO:007200114 | Thyroid | PTC | renal system development | 135/5968 | 302/18723 | 1.76e-06 | 2.43e-05 | 135 |
GO:006056219 | Thyroid | PTC | epithelial tube morphogenesis | 141/5968 | 325/18723 | 7.52e-06 | 8.73e-05 | 141 |
GO:00032794 | Thyroid | PTC | cardiac septum development | 54/5968 | 103/18723 | 1.17e-05 | 1.29e-04 | 54 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SALL1 | SNV | Missense_Mutation | novel | c.2707N>C | p.Ser903Pro | p.S903P | Q9NSC2 | protein_coding | deleterious(0.01) | probably_damaging(0.939) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD |
SALL1 | SNV | Missense_Mutation | rs750514153 | c.1192N>A | p.Ala398Thr | p.A398T | Q9NSC2 | protein_coding | tolerated(0.09) | benign(0.026) | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
SALL1 | SNV | Missense_Mutation | | c.356T>A | p.Leu119His | p.L119H | Q9NSC2 | protein_coding | tolerated(0.21) | benign(0.371) | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | | CR |
SALL1 | SNV | Missense_Mutation | | c.3080G>A | p.Arg1027Lys | p.R1027K | Q9NSC2 | protein_coding | tolerated(0.4) | probably_damaging(0.924) | TCGA-AC-A62X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SALL1 | SNV | Missense_Mutation | | c.2487N>A | p.Met829Ile | p.M829I | Q9NSC2 | protein_coding | tolerated(0.17) | benign(0.04) | TCGA-AR-A0TP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
SALL1 | SNV | Missense_Mutation | | c.2440N>A | p.Asp814Asn | p.D814N | Q9NSC2 | protein_coding | tolerated(0.1) | possibly_damaging(0.728) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
SALL1 | SNV | Missense_Mutation | | c.2869G>T | p.Ala957Ser | p.A957S | Q9NSC2 | protein_coding | tolerated(0.64) | benign(0.003) | TCGA-BH-A1F0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SALL1 | SNV | Missense_Mutation | rs766578948 | c.3719N>T | p.Ala1240Val | p.A1240V | Q9NSC2 | protein_coding | tolerated(0.12) | probably_damaging(0.994) | TCGA-E9-A1NE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
SALL1 | SNV | Missense_Mutation | | c.1406N>A | p.Arg469His | p.R469H | Q9NSC2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-E9-A1NF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
SALL1 | SNV | Missense_Mutation | | c.343G>C | p.Glu115Gln | p.E115Q | Q9NSC2 | protein_coding | deleterious(0.01) | benign(0.005) | TCGA-EW-A1PB-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |